Insulin-IGF signaling affects cell transformation in the BALB/c 3T3 cell model
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Insulin-IGF signaling affects cell transformation in the BALB/c 3T3 cell model
Authors
Keywords
-
Journal
Scientific Reports
Volume 6, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-11-16
DOI
10.1038/srep37120
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- AKT in cancer: new molecular insights and advances in drug development
- (2016) Prabhjot S. Mundi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Yin and yang of 4E-BP1 in cancer
- (2016) Ren Wang et al. CELL CYCLE
- Diabetes and Cancer: a Review of Current Knowledge
- (2016) J. Wojciechowska et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Impact of metformin on metastases in patients with breast cancer and type 2 diabetes
- (2016) Louis Jacob et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer
- (2016) Juergen M. Schanzer et al. mAbs
- The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma
- (2016) Claudia Pivonello et al. Oncotarget
- Improvement of the BALB/c-3T3 cell transformation assay: a tool for investigating cancer mechanisms and therapies
- (2016) Doerte Poburski et al. Scientific Reports
- Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study
- (2015) Martin Fassnacht et al. LANCET ONCOLOGY
- Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K
- (2015) Rupert Courtnay et al. MOLECULAR BIOLOGY REPORTS
- The expanding role of mTOR in cancer cell growth and proliferation
- (2015) Marie Cargnello et al. MUTAGENESIS
- Expression and clinical significance of mammalian target of rapamycin/P70 ribosomal protein S6 kinase signaling pathway in human colorectal carcinoma tissue
- (2015) QINGJUN LU et al. Oncology Letters
- GSK-3 as potential target for therapeutic intervention in cancer
- (2015) James A. McCubrey et al. Oncotarget
- Rapamycin: One Drug, Many Effects
- (2014) Jing Li et al. Cell Metabolism
- Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors
- (2014) R. L. Jones et al. CLINICAL CANCER RESEARCH
- A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors
- (2014) I. Puzanov et al. CLINICAL CANCER RESEARCH
- Effects of the Antitumor Drug OSI-906, a Dual Inhibitor of IGF-1 Receptor and Insulin Receptor, on the Glycemic Control, β-Cell Functions, and β-Cell Proliferation in Male Mice
- (2014) Jun Shirakawa et al. ENDOCRINOLOGY
- Targeting RAS–ERK signalling in cancer: promises and challenges
- (2014) Ahmed A. Samatar et al. NATURE REVIEWS DRUG DISCOVERY
- Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models
- (2013) S. A. Flanigan et al. CLINICAL CANCER RESEARCH
- In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer
- (2013) PREMILA D. LEIPHRAKPAM et al. ONCOLOGY REPORTS
- Overexpression of the Insulin Receptor Isoform A Promotes Endometrial Carcinoma Cell Growth
- (2013) Chun-Fang Wang et al. PLoS One
- Latest insights into the risk of cancer in diabetes
- (2013) Hiroshi Noto et al. Journal of Diabetes Investigation
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Insulin resistance and cancer: the role of insulin and IGFs
- (2012) Sefirin Djiogue et al. ENDOCRINE-RELATED CANCER
- Obesity, type 2 diabetes, and cancer: the insulin and IGF connection
- (2012) Dara Hope Cohen et al. ENDOCRINE-RELATED CANCER
- Wnt signaling from membrane to nucleus: β-catenin caught in a loop
- (2012) Cara Jamieson et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- The decline and fall of the IGF-I receptor
- (2012) Renato Baserga JOURNAL OF CELLULAR PHYSIOLOGY
- Rodent cell transformation assays—A brief historical perspective
- (2012) Leonard M. Schechtman MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS
- Photo catalogue for the classification of foci in the BALB/c 3T3 cell transformation assay
- (2012) Kiyoshi Sasaki et al. MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS
- Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis
- (2012) Hiroshi Noto et al. PLoS One
- A Kinome-Wide Screen Identifies the Insulin/IGF-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Breast Cancer
- (2011) E. M. Fox et al. CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- 18FDG-PET Predicts Pharmacodynamic Response to OSI-906, a Dual IGF-1R/IR Inhibitor, in Preclinical Mouse Models of Lung Cancer
- (2011) E. T. McKinley et al. CLINICAL CANCER RESEARCH
- Lithium reduces tumorigenic potential in response to EGF signaling in human colorectal cancer cells
- (2011) Morgado-Díaz INTERNATIONAL JOURNAL OF ONCOLOGY
- Epithelial-Mesenchymal Transition Predicts Sensitivity to the Dual IGF-1R/IR Inhibitor OSI-906 in Hepatocellular Carcinoma Cell Lines
- (2011) H. Zhao et al. MOLECULAR CANCER THERAPEUTICS
- ECVAM prevalidation study on in vitro cell transformation assays: General outline and conclusions of the study
- (2011) Raffaella Corvi et al. MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS
- The AMPK signalling pathway coordinates cell growth, autophagy and metabolism
- (2011) Maria M. Mihaylova et al. NATURE CELL BIOLOGY
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
- (2011) Michelle C. Mendoza et al. TRENDS IN BIOCHEMICAL SCIENCES
- Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E
- (2010) Andrew C. Hsieh et al. CANCER CELL
- 4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors
- (2010) Qing-Bai She et al. CANCER CELL
- BALB/c 3T3 cell transformation assay for the prediction of carcinogenic potential of chemicals and environmental mixtures
- (2010) Maria Grazia Mascolo et al. TOXICOLOGY IN VITRO
- Insulin Receptor Isoforms and Insulin Receptor/Insulin-Like Growth Factor Receptor Hybrids in Physiology and Disease
- (2009) Antonino Belfiore et al. ENDOCRINE REVIEWS
- Targeting the IGF1 axis in cancer proliferation
- (2009) Ilan Bruchim et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor
- (2009) Mark J Mulvihill et al. Future Medicinal Chemistry
- Common corruption of the mTOR signaling network in human tumors
- (2009) S Menon et al. ONCOGENE
- Comparison of gene expression profiles in BALB/c 3T3 transformed foci exposed to tumor promoting agents
- (2009) Lin Ao et al. TOXICOLOGY IN VITRO
- Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival
- (2008) J. H. Law et al. CANCER RESEARCH
- The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
- (2008) Ralph J. DeBerardinis et al. Cell Metabolism
- Identification of tumor promotion marker genes for predicting tumor promoting potential of chemicals in BALB/c 3T3 cells
- (2008) Hideki Maeshima et al. TOXICOLOGY IN VITRO
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started